NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

$5.17
-0.20 (-3.72%)
(As of 04:27 PM ET)
Today's Range
$5.06
$5.37
50-Day Range
$5.16
$8.46
52-Week Range
$2.78
$8.85
Volume
6,305 shs
Average Volume
29,576 shs
Market Capitalization
$28.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Aprea Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
199.8% Upside
$15.50 Price Target
Short Interest
Healthy
2.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$71,952 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.38) to ($0.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

280th out of 909 stocks

Pharmaceutical Preparations Industry

121st out of 423 stocks

APRE stock logo

About Aprea Therapeutics Stock (NASDAQ:APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

APRE Stock Price History

APRE Stock News Headlines

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Aprea Therapeutics CFO buys $7,362 in company stock
Aprea Therapeutics Inc (APRE)
Aprea Therapeutics Inc.
See More Headlines
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/24/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APRE
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+206.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,290,000.00
Pretax Margin
-2,450.60%

Debt

Sales & Book Value

Annual Sales
$580,000.00
Book Value
$4.54 per share

Miscellaneous

Free Float
4,295,000
Market Cap
$27.48 million
Optionable
No Data
Beta
1.03
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Oren Gilad Ph.D. (Age 56)
    Co-Founder, CEO, President & Director
    Comp: $520.84k
  • Mr. John P. Hamill CPA (Age 60)
    Senior VP, CFO, Principal Accounting Officer & Secretary
  • Dr. Dansu Li Ph.D.
    Head of Technology
  • Dr. Lars B. Abrahmsen Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
  • Dr. Michel Afargan Ph.D.
    Head of Pharmacology Development
  • Mr. Ze'ev Weiss B.Sc. (Age 62)
    C.P.A., Chief Business Advisor
  • Ms. Andrea Epstein
    Controller

APRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APRE shares.
View APRE analyst ratings
or view top-rated stocks.

What is Aprea Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Aprea Therapeutics' shares. Their APRE share price targets range from $11.00 to $20.00. On average, they anticipate the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 199.8% from the stock's current price.
View analysts price targets for APRE
or view top-rated stocks among Wall Street analysts.

How have APRE shares performed in 2024?

Aprea Therapeutics' stock was trading at $4.70 at the beginning of 2024. Since then, APRE shares have increased by 10.0% and is now trading at $5.17.
View the best growth stocks for 2024 here
.

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 105,800 shares, a decline of 9.6% from the March 15th total of 117,100 shares. Based on an average daily trading volume, of 34,600 shares, the days-to-cover ratio is currently 3.1 days. Approximately 2.4% of the shares of the company are sold short.
View Aprea Therapeutics' Short Interest
.

When is Aprea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our APRE earnings forecast
.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.36. The firm earned $0.01 million during the quarter, compared to analyst estimates of $0.33 million.

When did Aprea Therapeutics' stock split?

Shares of Aprea Therapeutics reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APRE) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners